Awakn Life Sciences Announces Private Placement
Toronto, Ontario--(Newsfile Corp. - April 26, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (the "Company"), a biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), is pleased to announce a non-brokered private placement financing for gross proceeds of up to $3,000,000 through the issuance of up to 6,521,739 units in the capital of the Company (the "Units") at a price of $0.46 per Unit (the "Offering"),...
2023-04-26 8:18 AM EDT
Awakn Life Sciences Signs Collaboration Agreement with University of Exeter for Upcoming Phase III Trial
Toronto, Ontario--(Newsfile Corp. - April 18, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announces that it has signed a collaboration agreement with the University of Exeter (UoE) putting in place a framework for the upcoming Phase III trial exploring the use of ketamine-assisted therapy to treat Severe AUD. The agreement formalizes...
2023-04-18 7:30 AM EDT
Awakn Life Sciences Increases Ownership of Awakn Bristol to 100% and Provides Corporate Update
Toronto, Ontario--(Newsfile Corp. - April 12, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), is today providing a corporate update.Dr. Ben Sessa has resigned from his role as Head of Psychedelic Medicine at Awakn and will leave the business effective April 13. As a result of Dr. Sessa leaving Awakn, Dr. Sessa has agreed to transfer his...
2023-04-12 7:30 AM EDT
Awakn Life Sciences Signs Its Fourth Licensing Partnership Agreement in North America, and First in California
Toronto, Ontario--(Newsfile Corp. - February 28, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announces today it has signed its fourth Licensing Partnership agreement in North America. The agreement is with Ken Starr MD Wellness Group an addiction treatment facility in California. This is the first Licensing Partnership Awakn has signed...
2023-02-28 7:30 AM EST
Awakn Life Sciences Signs Its First Licensing Partnership Agreement in Europe
Toronto, Ontario--(Newsfile Corp. - February 21, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announces today it has signed its first Licensing Partnership agreement in Europe with a healthcare consortium currently operating in stealth-mode ("Portuguese Partner"). The agreement will support the Portuguese Partner's strategy to launch a...
2023-02-21 7:51 AM EST
Awakn Life Sciences Announces the Opening of Its Fourth Clinic
Toronto, Ontario--(Newsfile Corp. - February 14, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announces today that Awakn Clinics Trondheim is now open and will begin treating clients next week. This will be the second Awakn clinic operating in Norway with a further two clinics already based in the UK.Awakn Clinics Trondheim is a...
2023-02-14 7:30 AM EST
Awakn Life Sciences Initiates Feasibility Study for MDMA Using Catalent's Zydis Orally Disintegrating Tablet (ODT) Technology
Toronto, Ontario--(Newsfile Corp. - February 9, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), today announced it has initiated a feasibility study of MDMA leveraging Catalent's proprietary Zydis® ODT fast dissolve technology.Zydis ODT is a unique, freeze-dried, oral solid dosage form that disperses almost instantly in the mouth, allowing...
2023-02-09 7:30 AM EST
Awakn Life Sciences Responds to OTC Markets Request on Recent Promotional Activity
Toronto, Ontario--(Newsfile Corp. - February 8, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announces that it has been requested by OTC Markets Group Inc. ("OTC Markets") to issue this statement about promotional activity concerning its common stock.On February, 6, 2023, OTC Markets informed the Company that it became aware of certain...
2023-02-08 6:30 PM EST
Awakn Life Sciences Granted Fast-Track Designation from UK Regulator for Ketamine-Assisted Therapy for Alcohol Use Disorder
Toronto, Ontario--(Newsfile Corp. - February 7, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announces today the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has granted Awakn an Innovation Passport as part of the Innovative Licensing and Access Pathway (ILAP) for its proprietary ketamine-assisted therapy for the...
2023-02-07 7:30 AM EST
Awakn Life Sciences Initiates Investigative Study of Novel Formulation of (S)-ketamine to Assess Dissociative Effect
Toronto, Ontario--(Newsfile Corp. - January 24, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announces today it has initiated an investigative study to establish the dissociative effect of a proprietary and patent pending formulation of (S)-ketamine and optimized route of administration to support commercialization in due course.Today's...
2023-01-24 7:30 AM EST
Awakn Life Sciences Reports Strong Q3 2022 Results with 27% Revenue Growth
Toronto, Ontario--(Newsfile Corp. - December 15, 2022) - Awakn Life Sciences Corp.(NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a biotechnology company, researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announced today its financial results and business highlights for the three months ended October 31, 2022. All results are reported under International Financial Reporting Standards ("IFRS") and in Canadian...
2022-12-15 7:30 AM EST
Awakn Life Sciences' Phase III Trial to Be Delivered in the UK National Health Service (NHS)
Toronto, Ontario--(Newsfile Corp. - December 13, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a revenue-generating biotechnology company researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announces that its Phase III clinical trial exploring the use of ketamine-assisted therapy for the treatment of severe AUD will be delivered across seven NHS sites in the UK. The trial has...
2022-12-13 7:30 AM EST
Awakn Life Sciences Announces Signing of Lease for Second Clinic in Norway
Toronto, Ontario--(Newsfile Corp. - December 1, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a revenue-generating biotechnology company researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announces today the signing of a 5-year lease to open Awakn Clinics Trondheim. The new clinic is part of the second stage of Awakn's Nordic expansion plans, following on from last week's...
2022-12-01 7:30 AM EST
Awakn Life Sciences Announces Location for Larger Oslo Clinic
Toronto, Ontario--(Newsfile Corp. - November 23, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a revenue-generating biotechnology company researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announces today the signing of a 5-year lease to open a larger Awakn Clinics Oslo. The move to the new Oslo premises is the first stage of Awakn's Nordic expansion plans. Awakn Clinics Oslo's...
2022-11-23 7:30 AM EST
Awakn Life Sciences Announces Closing of Private Placement
Toronto, Ontario--(Newsfile Corp. - November 17, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a revenue-generating biotechnology company researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), is pleased to announce that, further to its press release dated September 15, 2022, it has closed a second and final tranche (the "Second Tranche") of its previously announced non-brokered...
2022-11-17 7:30 AM EST
Awakn Life Sciences Signs Its Third Licensing Partnership Agreement in North America, and First in New York
Toronto, Ontario--(Newsfile Corp. - November 9, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a revenue-generating biotechnology company researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announces it has signed its third Licensing Partnership agreement in North America. The agreement is with Nushama a leading network of ketamine-assisted therapy centers that exist to humanize...
2022-11-09 7:30 AM EST
Awakn Life Sciences Secures Funding to Expand Nordic Commercial Operations
Toronto, Ontario--(Newsfile Corp. - October 25, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a revenue-generating biotechnology company researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), today announces that its wholly-owned subsidiary Awakn Oslo AS ("Awakn Oslo") has entered into a debt financing agreement (the "Loan Agreement") with TD Veen AS (the "Lender"), a family-owned,...
2022-10-25 7:30 AM EDT
Awakn Life Sciences Reports Strong Q2 2022 Results
Q2Awakn also announces closing of first tranche of private placement financingToronto, Ontario--(Newsfile Corp. - September 15, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company, researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announced today its financial results and business highlights for the three months ended July 31, 2022. All results are reported...
2022-09-15 7:30 AM EDT
Awakn Life Sciences Signs Drug Development Agreement with Catalent for Zydis(R) Technology (An Orally Disintegrating Tablet) to Conduct Feasibility Studies to Improve Differentiation of Its MDMA Program
Toronto, Ontario--(Newsfile Corp. - September 12, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a revenue-generating biotechnology company researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), today announces it has signed a drug development agreement with Catalent, the global leader in enabling biopharma, cell, gene, and consumer health partners to optimize development, launch,...
2022-09-12 7:30 AM EDT
Awakn Life Sciences Signs Agreement with a Leading Drug Development Company to Deepen IP Moat for Its Lead Program
Toronto, Ontario--(Newsfile Corp. - August 25, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a revenue-generating biotechnology company researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announced today it has signed a twelve month option agreement with a leading drug development, manufacturing, and delivery systems company to in-license a proprietary formulation and route of...
2022-08-25 7:30 AM EDT